Literature DB >> 2690126

Amyloid beta protein and the basis for Alzheimer's disease.

G G Glenner1.   

Abstract

The amyloid fibril protein isolated from the cerebrovascular amyloid deposits seen in 92% of cases of Alzheimer's disease and 100% of cases of Down's syndrome over the age of 40 has been shown to have a previously unknown amino acid sequence. This protein has been designated beta protein (beta P) and the type amyloid fibrils, ACv beta. Polyclonal and monoclonal antibodies raised to a synthetic peptide comprising the first 10 amino acids of beta P localized both to cerebrovascular amyloid deposits as well as to the amyloid cores of all "senile" plaques. An amino acid sequence analysis based on that of the beta P has been reported indicating that the plaque amyloid fibril deposits are also composed of beta P. These deposits must cause severe disruption of neuronal fibers. Thus beta P in the form of amyloid deposits seems intrinsic to the destruction of neuronal competence and thus to the ensuing dementia of Alzheimer's disease. Since proteolysis converts the beta P precursor (Pre beta P) into amyloid fibrils, it is possible that 1) an abnormality in synthesis of the Pre beta P, perhaps during post-transitional events, or 2) an abnormality in proteolytic processing occurs to afford beta P deposits and the pathologic changes in Alzheimer's disease. Regardless of the processing abnormality, beta P represents a major component in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690126

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  8 in total

1.  Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Authors:  John Hardy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

Review 2.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

Review 3.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

Review 4.  Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.

Authors:  Huiyuan Li; Farid Rahimi; Gal Bitan
Journal:  ACS Chem Neurosci       Date:  2016-07-05       Impact factor: 4.418

5.  Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone.

Authors:  Puttur Santhoshkumar; Krishna K Sharma
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

Review 6.  APP Function and Lipids: A Bidirectional Link.

Authors:  Marcus O W Grimm; Janine Mett; Heike S Grimm; Tobias Hartmann
Journal:  Front Mol Neurosci       Date:  2017-03-10       Impact factor: 5.639

7.  Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer's disease.

Authors:  Sheena E B Tyler; Luke D K Tyler
Journal:  Nat Prod Bioprospect       Date:  2022-08-23

8.  Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.

Authors:  Jie-Jian Kou; Jun-Zhuo Shi; Yang-Yang He; Jiao-Jiao Hao; Hai-Yu Zhang; Dong-Mei Luo; Jun-Ke Song; Yi Yan; Xin-Mei Xie; Guan-Hua Du; Xiao-Bin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.